Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Shares Issued
Ratios

Immuneering (IMRX) Gross Profit (2020 - 2022)

Immuneering has reported Gross Profit over the past 3 years, most recently at $455.0 for Q4 2022.

  • Quarterly results put Gross Profit at $455.0 for Q4 2022, up 102.74% from a year ago — trailing twelve months through Sep 2023 was $455.0 (down 99.68% YoY), and the annual figure for FY2022 was $158830.0, down 82.86%.
  • Gross Profit for Q4 2022 was $455.0 at Immuneering, down from $19037.0 in the prior quarter.
  • Over the last five years, Gross Profit for IMRX hit a ceiling of $367568.0 in Q3 2020 and a floor of -$16630.0 in Q4 2021.
  • Median Gross Profit over the past 3 years was $191847.0 (2020), compared with a mean of $171718.7.
  • Biggest five-year swings in Gross Profit: plummeted 108.67% in 2021 and later soared 102.74% in 2022.
  • Immuneering's Gross Profit stood at $191847.0 in 2020, then crashed by 108.67% to -$16630.0 in 2021, then soared by 102.74% to $455.0 in 2022.
  • The last three reported values for Gross Profit were $455.0 (Q4 2022), $19037.0 (Q3 2022), and $46486.0 (Q2 2022) per Business Quant data.